Cell & Gene Therapy Supply Chain: Early Preparation is Key
Cell and gene therapy developers and their CDMO partners must employ strategic solutions to anticipate and mitigate supply chain issues as early as possible in the process. Organizations that can produce any necessary materials in house through vertical integration will hedge against shortages. For example, producing media and buffer in-house reduces the reliance on vendors, and provides redundant sources for this vital raw material. In early clinical development we add contingencies to buffer ourselves and look to validate alternative suppliers and raw materials as soon as possible. As a therapy progresses and we near commercial scale production we will have set ourselves up to employ a leaner process.
At the Center for Breakthrough Medicines (CBM), a pure-play CDMO focused on cell and gene therapies, we provide end-to-end support around both development and manufacturing. This level of service requires strong partnerships with key suppliers. Our ability to provide strong supply chain solutions is derived from a seasoned core team with some of the strongest credentials in the burgeoning cell and gene therapy marketplace…